The analysis and planning methods for competing risks model have been described in the literatures in recent decades, and non-inferiority clinical trials are helpful in current pharmaceutical practice.
Background
described the concept of generalized survival analysis, which mainly refers to multi-state model, of which single-event survival analysis and the competing risks model are special cases. Single-event survival analysis is used to analyze survival data in which an event can only occur once for each patient. In a competing risks framework, more than one type of event can occur to the patients under follow-up, and all of the events are absorbing (absorbing state). The competing event prevents the event of interest from occurring. Numerous studies have focused on methods for the inference and modeling of competing risks data in recent decades, but few designed studies that are based on a competing risks framework have been performed (Pintilie, 2002; Schulgen, 2005; Maki, 2006; Latouche, 2004; Latouche, 2007; Tai, 2015) .
Sample size determination is an important aspect of clinical trial planning and design. Sample size formulas have been published for trials in the presence of competing risks (Pintilie, 2002; Schulgen, 2005; Maki, 2006; Latouche, 2004; Latouche, 2007; Tai, 2015) , and the null hypothesis in all of these trials is no difference between two treatments, which is termed superiority testing. Some sample size formulas are developed based on the cause-specific hazard (CSH) ratio (Pintilie, 2002; Schulgen, 2005; Maki, 2006) , whereas others use the sub-distribution hazard (SDH) ratio (Latouche, 2004; Latouche, 2007) .
However, non-inferiority designs are necessary in some cases because similarity to an existing effective therapy can justify a product being on the market and providing more treatment options for patients. When competing risks are present, proportional sub-distribution hazards, Cox proportional hazards and marginal models can be used for descriptive purposes and inference. Parpia et al. (2013) discussed the performance of these methods in non-inferiority clinical trials in the presence of competing risks (NiCTCR) and indicated that aside from biological studies, the sub-distribution hazard model is preferred because of its advantage of intuitive explanation. Although non-inferiority method in clinical trials in the presence of competing risks is as necessary as method in clinical trials with single-event survival analysis, the lack of an applicable sample size determination method for planning NiCTCR has limited its development. Therefore, we present a sample size formula for NiCTCR in this paper.
The article is organized as follows. In Section 2, background information on competing risks and associated modeling methods of competing risks are introduced. A sample size formula for NiCTCR with the Weibull survival time assumption is presented. A numerical simulation is conducted to verify the usefulness of the sample size formula in non-inferiority clinical trials in the presence of competing risks in Section 3, and the results from the simulation are presented. The presented formula for NiCTCR is illustrated with an example in Section 4. Section 5 discusses various considerations of parameter settings and potential arguments. Detailed technical derivations are provided in the Appendix.
Methods

Basic quantities of the competing risks model
More than one type of event can occur during the follow-up period in the framework of the competing risks model. In this paper, two events are considered without a loss of generality. The primary endpoint is the time to some negative event of interest, whereas a separate event is regarded as the competing event. The negative event of interest, for example, cancer death or progression of cancer, indicates that a high hazard rate corresponds to unsatisfactory efficacy. The occurrence of the 4 competing event may affect the event of interest. Some basic descriptive statistics and models for the framework of competing risks are provided in this section. The CSH function for the abovementioned event of interest is expressed as follows:
The risk set of CSH includes subjects who are still under follow-up and who have not experienced any event, i.e.,
The other basic descriptive statistic, the cumulative incidence function (CIF), is a measure of the actual probability of events because it considers the competing cause when estimating the incidence rate for the event of interest. Using the CIF as the basis for construction, the SDH for the event of interest is defined as follows:
A semi-parametric proportional hazards model for the SDH of the failure times of interest (Fine, 1999 ) is constructed as follows:
where 0 ( ) SD h t is the baseline sub-distribution hazard for the event of interest, and x and b denote the covariate and its coefficient, respectively.
Based on the definition of CSH, the sample size formula for comparing the CSHs in non-inferiority clinical trials is the same as that for comparing hazards in the Cox proportional hazard model (Formula (3) with 1 1   and a truncated exponential enrollment distribution in Crisp et al. (2008) ), as follows: Based on the abovementioned definitions and previous studies on the competing risks model (Lau, 2009; Putter, 2007) , the CSH censors the competing events, but such censoring is assumed to be non-informative because the censoring time is assumed to be independent of the event time. However, the SDH treats the competing event as the event of interest with infinite event time. As a result, an individual with a competing event remains in the risk set (Tai, 2011) . The SDH is a measure of association that reflects both the association of the treatment with the event of interest and the contribution of a competing event by actively maintaining individuals in the risk set.
Thus, the use of the proportional sub-distribution hazard model depicts the rules of a certain event more reasonably. Therefore, the sample size formula for NiCTCR presented in this study is based on the proportional sub-distribution hazard model and its statistics.
Sample size formula for NiCTCR
The hypotheses for non-inferiority clinical trials in the presence of competing risks are as follows:
i.e., 0 in the Appendix). The partial likelihood of the model (1) can be constructed as follows:
where I{CONDITION} is the indicator function, which returns to 1 when the CONDITION in the braces is true; otherwise, this function returns to 0. Similar to the assignment in Latouche et al. (2004) , 0 i x  and 1 i x  indicate that the ith subject is assigned to the control and experimental groups, respectively. The information is expressed as follows:
F is the cumulative incidence function of the censoring and is assumed to be identical in the two groups, and ( ) ; therefore, the following formula is obtained:
Finally, the sample size formula can be derived as follows:
implies the incidence rate of both groups, and #E implies the calculated events needed in two groups.
We assume that the survival time of the event of interest in both groups is Weibull 
where 1
x q denotes the probability that an individual who has not experienced any event occurrence undergoes the event of interest given that individual undergoes any event; i.e., 1 count of event of interest occuring in group count of any event occuring in group
Formula (6) can be derived from the sum of two single integrals as follows:
where
To plan a conservative trial, the hazard rate was based on the alternative hypothesis in Formula (3), which indicates that the cumulative incidence rates are identical in two groups, to ensure a predetermined power (Crisp, 2008) .
Simulations
To verify the performance of the sample size formula of NiCTCR, 10,000 simulations of 120 parameter combinations (Table A1 in the supporting material) were conducted by using R software (V2.15.2, http://www.R-project.org). The time to failure from each cause was generated using the indirect method (Beyersmann, 2011) . Fine and Gray assumed that the cumulative incidence function of the failure of interest and competing event in group x follow the following model:
Consequently, ( | , 0) Table 1 (and Table A1 in the supporting material).
The Fine-Gray proportional sub-distribution hazard model is used for modeling and estimating the confidence interval of SDH. Non-inferiority may be concluded when the upper limit of the two-sided 95% confidence interval for the SDH ratio does not exceed 0  . Type I error and power are calculated under the presetting situation where  for generating data is equal to 0  and 1  , respectively.
As shown in Figure 1 (and Table A1 in the supporting material), the incidence rates of the censoring and competing events were simulated from 70% to more than 
Example for NiCTCR
To illustrate the implications in terms of the sample size formulas for NiCTCR, we used the study of Schroder et al. (2009) as an example. In that study, a randomized controlled trial to evaluate the effect of early (EET, control group) versus delayed (DET, experimental group) endocrine treatment in patients with lymph node-positive prostate cancer was performed. The primary endpoint was overall survival from randomization to the day of death. The secondary endpoint was set as cancer death (CD) and non-cancer death (NCD). The Kaplan-Meier method and Cox proportional hazards model were used for the estimation, and the confidence intervals of the hazard rate of CD and NCD were used to test the non-inferiority of DET to EET with a non-inferiority margin of 1.5. In total, 234 patients were recruited to achieve 85% power and were randomly assigned at 1:1 to the EET and DET groups. In the CD comparison, NCD was treated as the competing risk.
The proposed formula was utilized for planning this trial. The required parameters were extracted from a figure (Fig. 4) q was equal to 0.737. Forty-one of 234 patients were prematurely withdrawn.
Therefore, we supposed that the censoring hazard rate would equal 0.020 in the exponential censoring distribution. The sample size calculated from the presented sample size formula of NiCTCR is shown in Table 2 . Several scenarios for the three shape parameters, with and without random censoring, were considered.
A total of 110 events per group was required for the presented formula to achieve 85% power. When the survival time was exponentially distributed with and without censoring, 272 and 243 patients were required, respectively. If the hazard rate decreased, the required sample size was slightly larger than that of the constant hazard because of the smaller hazard rate, whereas 288 and 269 patients per group, with and without random censoring, respectively, were necessary to increase the hazard rate survival time.
When we used the sample size formula, Formula (2), for a single event or CSH in non-inferiority clinical trials (Crisp, 2008) instead of the proposed sample size formula, Formula (5), all of the sample sizes calculated were smaller than those calculated for the proportional SDH model. Single-event survival analysis overestimates the incidence proportion of the event of interest by treating the competing event as censoring.
Consequently, in studies involving sub-distribution modeling, applying the sample size formula of single-event non-inferiority clinical trials may underestimate the sample size required and result in underpowered trials.
Results and discussion
In this paper, we derived a sample size formula based on the proportional sub-distribution hazard model using the Wald test in non-inferiority clinical trials, which is used for studies with a primary endpoint based on SDH. Simulations and an example
showed that the presented sample size formula can correctly estimate the required sample size. The presented formula is most applicable when SDH is employed to reveal the close to "real world" relationship between the treatment and endpoints when competing risks are present, whereas the sample size formula for CSH may be used when the objective is the theoretical relationship. In many cases, apart from biological studies, learning the experimental treatment's comprehensive effects on all events may be more beneficial and attractive for an intuitive explanation (Parpia et al., 2013) , and all the patients are treated in the real world where multiple events may occur. Thus, we recommend using the SDH as the primary endpoint in clinical trials when appropriate, with the presented formula to better estimate the sample size.
According to the guideline from FDA (U.S. Food and Drug Administration) for non-inferiority trials, the estimated treatment effect from the historical trials should be used to derive the non-inferiority margin for a non-inferiority trial. However, if the SDH model was not used in related studies, we suggest that the non-inferiority margin for SDH be calculated from the CSH by Lau's formula (Lau, 2009) . If neither SDH nor CSH is available, a pilot study might be more appropriate.
If 0 1   and 1 1   , the presented formula can be used for superiority testing.
The body of the presented formulas and the formula of Latouche (2004) look the same.
Nevertheless, the presented formula here is derived based on the Weibull distribution, where Latouche's formula is based on the exponential distribution. In addition, the calculation of parameter  in Latouche's formula is different from that of w in the denominator of the formula presented here.
One potential criticism of the competing risks application is that multiple events can be reasonably combined into a composite endpoint. For example, CD and NCD can be combined into overall survival if the detailed causes of death are not of interest and if the CD rate affected by NCD is not of concern. Nevertheless, not all events can be combined into a composite endpoint. For example, when the events defined are opposites, such as recovery vs. death for hospitalized patients with SARS (Chen, 2009), they cannot be combined into a composite endpoint. In practice, a competing risks model can reveal the underlying relationships among the studied events and variables, whereas a composite-endpoint method can simplify the analysis strategy without missing too much important information. More details are provided in recently published papers (Mell, 2010; Rauch, 2013) . time can be adopted in Formula (6) to cover more general situations.
In this paper, the uniform accrual time was employed, i.e., the number of subjects enrolled by a Poisson distribution. In addition, the accrual rate was constant over the interval [0, R] . In reality, this accrual rate can be increasing or decreasing over time or can follow a non-monotone pattern. A constant rate was assumed to simplify the equations; however, other distributions have been discussed by various researchers (Maki, 2006; Crisp, 2008) . For instance, other distributions can be used by incorporating the density function into Equation (6) and by replacing 1/ R .
Appendix
A: Proof of the sample size formula in NiCTCR.
The hypothesis is as follows: The independent variable x is an indicator of groups. The x = 0 represents the control group and x = 1 represents the experimental group. The risk set at time t can be written as follows: is the event code of the ith subject. The log partial likelihood can be expressed as follows:
According to the Fine-Gray's paper (1999) , the score statistic is expressed as follows:
The information can be derived by the following formula:
and 2 j j x x  , then Formula A.1 can be rewritten as follows: 
Let x F and x f be the cumulative incidence function and sub-density function of the event of interest in group x and x F be the cumulative incidence function of censoring. N denotes the total number of subjects required in the two groups. x p denotes the assignment proportion of subjects to group x. Therefore, xi Y can be rewritten as follows:
, the Equation (A.3) can be rewritten as follows:
is most common. In such a situation and under the alternative hypothesis, the following formula can be noted as follows: 
. (0) )
After considering the inverse normal distribution function for two sides of the equation,
we can obtain the following formula:
The total number of subjects can be calculated from the following formula: (Beyersmann, 2011; Pintilie, 2006) with the Weibull survival time assumption. In this assumption, xD q denotes the probability that an individual who has experienced an event, undergoes the event of interest. D k denotes the shape parameter of the event D, which is identical across two groups. xD Table 1 
